Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 6/20 | 0.62 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.57 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.57 |
| ▸ | CASR | P41180 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5424769 | 0.89 | UTS2R (0.52) | UTS2RROCK2ROCK1CASRMEN1 | |
| SCHEMBL5403645 | 0.85 | ROCK2 (0.54) | UTS2RROCK2ROCK1CASRMEN1 | |
| SCHEMBL5400966 | 0.84 | ROCK2 (0.51) | UTS2RROCK2ROCK1CASRMEN1 | |
| SCHEMBL5418594 | 0.83 | ROCK2 (0.53) | UTS2RROCK2ROCK1CASRATM | |
| SCHEMBL5418585 | 0.83 | ROCK2 (0.53) | UTS2RROCK2ROCK1CASRATM | |
| SCHEMBL5417277 | 0.81 | ROCK2 (0.47) | UTS2RROCK2ROCK1CASRMEN1 | |
| SCHEMBL5414392 | 0.80 | HTR3A (0.57) | ROCK2ROCK1CASRMEN1KMT2A | |
| SCHEMBL5418272 | 0.80 | HTR3A (0.57) | ROCK2ROCK1CASRMEN1KMT2A | |
| SCHEMBL5406811 | 0.80 | HTR3A (0.57) | ROCK2ROCK1CASRMEN1KMT2A | |
| SCHEMBL5409846 | 0.79 | ROCK2 (0.64) | UTS2RROCK2ROCK1CASRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202269-B2 | GlyT2 modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-10 | — | — | US | claimed |
| US-20050119245-A1 | GlyT2 modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-06-02 | — | — | US | claimed |
| US-7202269-B2 | GlyT2 modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-10 | — | — | US | disclosed |
| US-7202269-B2 | GlyT2 modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-10 | — | — | US | disclosed |
| US-7202269-B2 | GlyT2 modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-10 | — | — | US | disclosed |
| US-20050119245-A1 | GlyT2 modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-06-02 | — | — | US | disclosed |
| WO-2005044810-A1 | GLYT2 MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119245-A1 | GlyT2 modulators | GLRB, GLRA1, GLRA2 | UTS2R 855/4885ROCK2 3542/4885ROCK1 3815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.